vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and OXFORD INDUSTRIES INC (OXM). Click either name above to swap in a different company.
OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -20.7%, a 31.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -0.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-47.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -3.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.
ANIP vs OXM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $307.3M |
| Net Profit | $27.5M | $-63.7M |
| Gross Margin | — | 60.3% |
| Operating Margin | 14.1% | -27.7% |
| Net Margin | 11.1% | -20.7% |
| Revenue YoY | 29.6% | -0.2% |
| Net Profit YoY | 367.5% | -1517.6% |
| EPS (diluted) | $1.14 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $307.3M | ||
| Q3 25 | $227.8M | $403.1M | ||
| Q2 25 | $211.4M | $392.9M | ||
| Q1 25 | $197.1M | — | ||
| Q4 24 | $190.6M | $308.0M | ||
| Q3 24 | $148.3M | $419.9M | ||
| Q2 24 | $138.0M | $398.2M | ||
| Q1 24 | $137.4M | $404.4M |
| Q4 25 | $27.5M | $-63.7M | ||
| Q3 25 | $26.6M | $16.7M | ||
| Q2 25 | $8.5M | $26.2M | ||
| Q1 25 | $15.7M | — | ||
| Q4 24 | $-10.3M | $-3.9M | ||
| Q3 24 | $-24.2M | $40.6M | ||
| Q2 24 | $-2.3M | $38.4M | ||
| Q1 24 | $18.2M | $-60.1M |
| Q4 25 | — | 60.3% | ||
| Q3 25 | — | 61.4% | ||
| Q2 25 | — | 64.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 63.1% | ||
| Q3 24 | — | 63.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 60.9% |
| Q4 25 | 14.1% | -27.7% | ||
| Q3 25 | 15.9% | 6.3% | ||
| Q2 25 | 6.6% | 9.2% | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | -2.0% | ||
| Q3 24 | -13.8% | 12.5% | ||
| Q2 24 | 3.7% | 13.2% | ||
| Q1 24 | 14.8% | -20.1% |
| Q4 25 | 11.1% | -20.7% | ||
| Q3 25 | 11.7% | 4.1% | ||
| Q2 25 | 4.0% | 6.7% | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | -5.4% | -1.3% | ||
| Q3 24 | -16.3% | 9.7% | ||
| Q2 24 | -1.7% | 9.6% | ||
| Q1 24 | 13.2% | -14.9% |
| Q4 25 | $1.14 | $-4.28 | ||
| Q3 25 | $1.13 | $1.12 | ||
| Q2 25 | $0.36 | $1.70 | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | $-0.25 | ||
| Q3 24 | $-1.27 | $2.57 | ||
| Q2 24 | $-0.14 | $2.42 | ||
| Q1 24 | $0.82 | $-3.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $8.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $528.0M |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $8.0M | ||
| Q3 25 | $262.6M | $6.9M | ||
| Q2 25 | $217.8M | $8.2M | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | $7.0M | ||
| Q3 24 | $145.0M | $18.4M | ||
| Q2 24 | $240.1M | $7.7M | ||
| Q1 24 | $228.6M | $7.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $29.0M |
| Q4 25 | $540.7M | $528.0M | ||
| Q3 25 | $505.8M | $597.1M | ||
| Q2 25 | $436.8M | $592.4M | ||
| Q1 25 | $418.6M | — | ||
| Q4 24 | $403.7M | $612.2M | ||
| Q3 24 | $405.9M | $621.6M | ||
| Q2 24 | $455.8M | $592.9M | ||
| Q1 24 | $452.0M | $560.9M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | $1.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-9.1M |
| Free Cash FlowOCF − Capex | $29.1M | $-47.9M |
| FCF MarginFCF / Revenue | 11.8% | -15.6% |
| Capex IntensityCapex / Revenue | 0.5% | 12.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-79.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-9.1M | ||
| Q3 25 | $44.1M | $83.5M | ||
| Q2 25 | $75.8M | $-3.9M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | $-18.2M | ||
| Q3 24 | $12.5M | $88.8M | ||
| Q2 24 | $17.4M | $32.9M | ||
| Q1 24 | $18.3M | $74.9M |
| Q4 25 | $29.1M | $-47.9M | ||
| Q3 25 | $38.0M | $52.3M | ||
| Q2 25 | $71.8M | $-27.4M | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $-56.9M | ||
| Q3 24 | $7.7M | $47.2M | ||
| Q2 24 | $13.0M | $21.0M | ||
| Q1 24 | $13.7M | $55.3M |
| Q4 25 | 11.8% | -15.6% | ||
| Q3 25 | 16.7% | 13.0% | ||
| Q2 25 | 34.0% | -7.0% | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | -18.5% | ||
| Q3 24 | 5.2% | 11.2% | ||
| Q2 24 | 9.4% | 5.3% | ||
| Q1 24 | 10.0% | 13.7% |
| Q4 25 | 0.5% | 12.6% | ||
| Q3 25 | 2.7% | 7.7% | ||
| Q2 25 | 1.9% | 6.0% | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | 12.6% | ||
| Q3 24 | 3.2% | 9.9% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | 4.8% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 5.00× | ||
| Q2 25 | 8.87× | -0.15× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.19× | ||
| Q2 24 | — | 0.86× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OXM
| Sales Channel Retail | $162.9M | 53% |
| Sales Channel Wholesale | $61.3M | 20% |
| Johnny Was | $45.4M | 15% |
| Sales Channel Food And Beverage | $29.3M | 10% |
| Other Foreign Countries | $9.0M | 3% |
